|
|
发表于 9-11-2009 06:39 PM
|
显示全部楼层
回复 478# miku 的帖子
我是cubizone的忠实自持者 |
|
|
|
|
|
|
|
|
|
|
|
发表于 9-11-2009 06:40 PM
|
显示全部楼层
回复 478# miku 的帖子
|
我是cubizone的忠实自持者 |
|
|
|
|
|
|
|
|
|
|
|
发表于 9-11-2009 10:55 PM
|
显示全部楼层
CVM - Thumb Up！ 最高 1.50 。。。。
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response --STUDIES SUP
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
--STUDIES SUPPORTIVE OF ROLE THAT TECHNOLOGY CAN PLAY IN TREATMENT OF H1N1 HOSPITALIZED PATIENTS
Mon Nov 09 09:40:00 2009
EST
VIENNA, Va., Nov 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
CEL-SCI Corporation (NYSE Amex: CVM) announced today that Dr. Kenneth S. Rosenthal,
Professor of Immunology and Microbiology of Northeastern Ohio Universities College
of Medicine and Pharmacy, reported on work conducted in collaboration with scientists
at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology. The
data was presented at the 7th GTCbio Vaccine: "All Things Considered" Conference
in Crystal City, Virginia.
Working with LEAPS vaccines for herpes simplex virus, HIV, rheumatoid arthritis
and most recently, H1N1 influenza, the scientists' studies show that LEAPS peptide
immunogens can convert precursor cells from mouse or humans to become dendritic
cells (DC), the cell that directs the subsequent immune response. These DCs produce
interleukin 12 (IL12p70), but without production of the pro-inflammatory cytokines
that promote symptoms of a cytokine storm, such as tumor necrosis factor alpha or
interleukin 1. Immunization with a LEAPS-immunogen for herpes simplex virus activates
a protective T cell immune response against the virus in mice while a LEAPS-immunogen
for treatment of rheumatoid arthritis (CEL-2000) reduces the production of the pro-inflammatory
cytokines to block the progression of disease in mouse models of rheumatoid arthritis.
Dr. Rosenthal commented, "LEAPS immunogens are unique in their ability to
simultaneously produce and activate a specific type of dendritic cell that can turn
on or modulate antigen specific T cell responses without generating the pro-inflammatory
cytokines associated with cytokine storm. The ability to activate the desired immune
response should make LEAPS immunogens inherently safe vaccines. Finding of similar
results for mouse and human cells in our laboratory studies adds confidence that
the effects in the body will be the same in mice and man. "
Geert Kersten, CEO of CEL-SCI Corporation said: "We feel that this new data
is encouraging and supportive of our H1N1 treatment for hospitalized patients where
the goal is to produce a specific anti H1N1 immune response that will steer the
immune system towards protection and away from a cytokine storm which may be responsible
for many patients' deaths."
CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology
allows the Company to direct an immune response against specific disease epitopes.
In the case of CEL-SCI's investigational LEAPS-H1N1 treatment, this involves non-changing
regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. This is intended
to enable stimulation of the specifically-needed immune responses, while avoiding
the administration of regions of H1N1, and other viruses, which may exacerbate the
problem of cytokine storm, which CEL-SCI scientists believe may be involved in the
death of some H1N1 patients.
The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell
interactions on the T-cell surface with synthetic peptides. The L.E.A.P.S. constructs
containing the antigenic disease epitope linked to a Immune / T-cell binding ligand
(I/TCBL) can be manufactured by peptide synthesis or by covalently linking the two
peptides. Depending upon the type of L.E.A.P.S. construct and I/TCBL used, CEL-SCI
is able to direct the outcome of the immune response towards the development of
T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector
T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore,
it would appear that the L.E.A.P.S. construct represents a chimeric peptide with
bi-functional behavior.
CEL-SCI Corporation is developing products that empower immune defenses.
Its lead product is Multikine(R) which is being readied for a global Phase III trial
in advanced primary head and neck cancer. CEL-SCI is also developing a treatment
for hospitalized H1N1 patients using it's L.E.A.P.S. technology platform, and expects
to soon finish the validation of it's state-of-the-art manufacturing facility in
Maryland.
For more information, please visit www.cel-sci.com
When used in this report, the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties which could cause actual
results to differ materially from those projected. Factors that could cause or contribute
to such differences include, lack of regulatory clearance to proceed with clinical
trials, an inability to duplicate the clinical results demonstrated in clinical
studies that have been completed or that are initiated in the future, timely development
of any potential products that can be shown to be safe and effective, unwillingness
of regulatory authorities to engage in further regulatory dialogue, receiving necessary
regulatory approvals, difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital, and the risk factors set forth
from time to time in CEL-SCI Corporation's SEC filings, including but not limited
to its report on Form 10- K/A for the year ended September 30, 2008. The Company
undertakes no obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
http://www.cel-sci.com/
Copyright (C) 2009 PR Newswire. All rights reserved
CVM,
VA-CEL-SCI-Corp-H1N1, BUSINESS, csta+stories, FINANCE, financenews, financenews+select, HEALTHCARE, hedge+funds,
prn, PUBCO+SELECT, PUBLIC+COMPANIES, WALL+STREET, |
|
|
|
|
|
|
|
|
|
|
|
发表于 9-11-2009 11:44 PM
|
显示全部楼层
上个星期五.......
NYSE/NASD/AMEX
| | ORDER NO | STOCK SYMBOL | STOCK NAME | STATUS | BUY / SELL | ORDER TYPE | LIMIT PRICE | STOP PRICE | PRICE (E) | QTY (S) | QTY (E) | TIME (S) | TIME (R) | SET CUR | MSG | | 839344 | CVM | Cel-Sci Corp | Done | Buy | Limit Order | 1.22 | --- | | 5000 | | Nov 6 2009 10:53PM | Nov 6 2009 10:53PM | USD | | | 839344 | CVM | Cel-Sci Corp | Done | Buy | Limit Order | 1.22 | --- | 1.22 | | 100 | Nov 6 2009 10:53PM | Nov 6 2009 10:53PM | USD | | | 839344 | CVM | Cel-Sci Corp | Done | Buy | Limit Order | 1.22 | --- | 1.22 | | 100 | Nov 6 2009 10:53PM | Nov 6 2009 10:53PM | USD | | | 839344 | CVM | Cel-Sci Corp | Done | Buy | Limit Order | 1.22 | --- | 1.22 | | 200 | Nov 6 2009 10:53PM | Nov 6 2009 10:53PM | USD | | | 839344 | CVM | Cel-Sci Corp | Done | Buy | Limit Order | 1.22 | --- | 1.22 | | 4600 | Nov 6 2009 10:53PM | Nov 6 2009 10:53PM | USD |
今天卖出......
| NYSE/NASD/AMEX | | ORDER NO | STOCK SYMBOL | STOCK NAME | STATUS | BUY / SELL | ORDER TYPE | LIMIT PRICE | STOP PRICE | PRICE (E) | QTY (S) | QTY (E) | TIME (S) | TIME (R) | SET CUR | MSG | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | | 5000 | | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 4100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD | | | 4390 | CVM | Cel-Sci Corp | Done | Sell | Limit Order | 1.37 | --- | 1.37 | | 100 | Nov 9 2009 10:35PM | Nov 9 2009 10:35PM | USD |
没有看到新闻,太早放了.
[ 本帖最后由 m.i.k.e 于 9-11-2009 11:47 PM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 9-11-2009 11:53 PM
|
显示全部楼层
原帖由 m.i.k.e 于 9-11-2009 11:44 PM 发表 
上个星期五.......
NYSE/NASD/AMEX
ORDER NOSTOCK SYMBOLSTOCK NAMESTATUSBUY / SELLORDER TYPELIMIT PRICESTOP PRICEPRICE (E)QTY (S)QTY (E)TIME (S)TIME (R)SET CURMSG839344CVMCel-Sci CorpDoneBuyLimit Ord ...
你的Below $1 的還有Hold著嗎？
我上星期5 投機15000Units 賣出10000Units，留5000Units 今天賣 1.36。
後來見新聞出，又立刻進5000Units 1.3698，5分鐘後賣 1.4302 。。。
這2天收獲不錯。
幾時你要來古晉？  |
|
|
|
|
|
|
|
|
|
|
|
发表于 9-11-2009 11:57 PM
|
显示全部楼层
原帖由 葉芬 于 9-11-2009 11:53 PM 发表 
你的Below $1 的還有Hold著嗎？
我上星期5 投機15000Units 賣出10000Units，留5000Units 今天賣 1.36。
後來見新聞出，又立刻進5000Units 1.3698，5分鐘後賣 1.4302 。。。
這2天收獲不錯。
幾時你要 ...
這2天收獲不錯。..............(恭喜!)
幾時你要來古晉？ ............(未来.)
晚安. |
|
|
|
|
|
|
|
|
|
|
|
发表于 9-11-2009 11:59 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 01:13 AM
|
显示全部楼层
大家好。我在langkawi。cvm请我去的。我有30粒cvm。我发觉我不应该在langkawi，去错地方了。不过berjaya的suite也很美。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 01:15 AM
|
显示全部楼层
|
不过一得一失。avii亏8million。不过不怕，avii只需要一个h1n1的关联消息就可以了。O(∩_∩)O谢谢 |
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 09:21 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 09:22 AM
|
显示全部楼层
The Cel-Sci (NYSE AMEX: CVM) Saga; Entertainment At Its Finest
There's lots of emails on Cel-Sci (NYSE AMEX: CVM), so I thought the best way to address the issue would be to simply publish an update, especially since this story is making for some very entertaining content.
CVM had its way in the markets this year until a free lance writer named Adam Feuerstein starting publishing some pretty scathing stuff about the company through Thestreet.com.
Here's a couple of facts that aren't controversial- CVM has used the new found massive interest in the stock to load up its treasury to levels never experienced by the company in 20 years. Since June, CVM has raised about $40 million in equity capital, and now has the strongest balance sheet in its history. The company is capable of getting a ways down the road in terms of therapy development with that kind of cash war chest.
CVM is trading by far the most massive volume it has ever traded. 11 million shares now daily, with spurts to 25 to 30 million shares. This stock has never seen this kind of volume.
CVM has captured the interest of investors by openly discussing the possibility of it's L.E.A.P.S. platform as a possible therapy for the H1N1 Swine flu.
All this volume and publicity has attracted the interest of Mr. Feuerstein, who seems to be on a one man mission to discredit the company any way he can.
This is all pretty transparent and entertaining stuff. While I have no evidence of any kind to support my thesis, an animal that walks like a duck, quacks like a duck, and has feathers like a duck, is probably a duck.
My guess- the duck is someone who is short a lot of CVM, and Feuerstein is the guy they're using to try to talk it down. Take his Nov 4th article wherein he accused the company of doing a deal with a non existant entity. Look at the chart as it relates to his scathing revelation.
I have absolutely no idea if the allegations in his article have any merit. Here's what I do know- the stock was really coming down hard the entire week before his smoking gun was revealed. To me, this suggests someone is very short this stock and needs an exit strategy. They're beating the stock down, hoping investors panic on the "expose" news and drive it down.
Apparently, the investment community of biotech speculators has really warmed up to this idea, as the stock made its low just prior to the hatchet job, and has since rebounded with a vengence.
CVM followed up by disclosing the venerable John Hopkins University School of Medicine would conduct an initial study. Specifically, it will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS H1N1 investigational therapy in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol.
The market loves it, and CVM is right back to about $1.40. Their credibility was challenged, but the Johns Hopkins thing seems to have righted the ship. It's pretty tough to make a case against Johns Hopkins in the medical world. Lest you think CVM will have a cure for H1N1 next week- think again. This is very preliminary stuff.
The bottom line- people keep asking me if CVM is the real deal, and I don't know. I don't have the technological background to even hazard a guess. I know they have a lot of cash, huge volume in their stock, a legion of fans who believe, and I'd bet a substantial amount there's a huge short in the stock.
Here's my advice. If you want to trade this idea, wait for the next drop, wait for the hatchet job article, then buy. I've been a target once already, which demonstrates a certain level of desperation. It had nothing to do with CVM today, yet he tried to make the equivalent of a regulatory parking ticket sound like I was an axe murderer.
Buy on Bashing. I'll bet they're going to keep trying. Long term- the technology will either prove out or it won't- I won't even guess. Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com
[ 本帖最后由 葉芬 于 10-11-2009 09:24 AM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 09:41 AM
|
显示全部楼层
Date Open High Low Last Change Volume % Change
11/09/09 1.31 1.50 1.31 1.41 +0.19 16484164 +15.57%
Composite Indicator
Trend Spotter TM Sell
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Hold
Short Term Indicators Average: 40% - Buy
20-Day Average Volume - 8636403
Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 13445463
Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 8355727
Overall Average: 48% - Buy
Price Support Pivot Point Resistance
1.41 1.22 1.41 1.60 |
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 10:01 AM
|
显示全部楼层
回复 512# 葉芬 的帖子
|
哇芬姐赚到笑, 几时买机票给我去sarawak探你?便宜的airasia也不用紧...哈哈 |
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 10:08 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 10:28 AM
|
显示全部楼层
再次給你們看看CVM未來3年的潛能。
http://caps.fool.com/Blogs/ViewP ... 1005698258648988900
Cel-Sci has a 3000 Percent Increase Potential
"In the next three years Cel-Sci could light up the Biotech world by
releasing Phase III results on a new product called Multikine®.
Multikine® is CEL-SCI’s late stage cancer product, which is an
immunotherapeutic agent for first-line standard of care treatment in
head and neck cancer patients. The drugs approach is different in the
way it fights against cancer, by directly affecting both the tumor
cells and by activating an anti-tumor immune response by the body.
This multipronged approach has produced fabulous Phase II results.
Multikine achieved a 33% improvement in median overall survival at a
median of 3.5 years post surgery with no adverse events. Along with
these impressive safety and efficacy results, Multikine showed a 50%
reduction in tumor cells, 12% complete response, 8% increase in the
Local Regional Control.
Folks I’m not usually this gitty, but the Phase II results are just
not seen like this! I also like the risk factors ahead. Multikine will
only need to demonstrate a 10% improvement in overall survival for the
Phase III trials to be successful. We have a good 20% to play with
from the Phase II results.
So why is Cel-Sci’s stock at $0.48 for today’s close and its market
cap sitting on a measly 62M? Its because Wall Street is wondering why
a US partner has not yet been identified if you ask me. So why am I
not worried about this pending risk? Because TEVA has already signed
for the Israeli market and they are about the most conservative
company known to man on the branded side. They see the clinical risk
being very low and the potential for a best in class product being
high – just like I do!
Before I get too long winded let me tell you a few other reasons why I
like the stock; Cel-Sci has enough cash until next March (unusual for
Biotech’s in this credit climate), has only 130M shares outstanding,
and is finishing up on its manufacturing facility where it plans to
make its Phase III clinical trial material.
As with the other Biotech’s I’ve recommended I’m in for a handsome
sum!
I’ll keep you posted" |
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 11:20 AM
|
显示全部楼层
对自已买进的股保持正面和乐观的态度是件好事,但是千万要小心解读别人的看法.
在这里,很多新人都在看着你放上的讯息来决定买进.你在放上这些转帖时,有必要过滤和谨慎.
想当年, CTIC 也是被唱到多好,(在国外,还有一大堆股东准备到 Las Vegas 庆祝), 结果呢......
[ 本帖最后由 m.i.k.e 于 10-11-2009 11:22 AM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 01:02 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 01:31 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 01:38 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 10-11-2009 03:04 PM
|
显示全部楼层
Jim Cramer's 8 Picks for Cancer's Cure
http://www.benzinga.com/media/jim-cramer/38355/jim-cramer-names-his-best-picks-for-cancer-cures-bmy-imgn-pfe-dndn-exel
Cancer is one of the most devastating diseases in the planet. Cancer has killed over half a million American and it continues to grow. In fact, almost everyone knows a family member, a friend or a member of the community that has been touched by this disease.
CNBC,com’s Jim Cramer reveals his Picks for the best companies that are working on Cancer Cures and Treatments. In that list, you can find Bristol Myers Squibb (NYSE: BMY) . The smart acquisition strategy of Bristol Myers Squibb has brought in seven more companies since 2000. One company is Medarex which is working on a drug for the treatment of Metastic Melanoma. Currently, the drug is in its third stage of development. BMY shares went up 1.81% to 23.05 in today’s trading.
Pfizer (NYSE: PFE), another of Cramer’s Picks, offers one of the most diversified list of drugs among health care companies and the acquisition of Wyeth can only help increase its income from cancer treatment drugs. Currently, Pfizer has 22 cancer drugs including Aromasin, used for Breast Cancer treatment; Sutent, a drug that limits blood into tumors; and Campotar, a drug used to treat colon cancer. Pfizer rose to 2.77% to 17.43.
Another one of Cramer's Picks is Immunogen (NASDAQ: IMGN). Immunogen used to be one of the highest priced stocks in Nasdaq in year 2000 but soon fell because of clinical trials that had less than favorable result. Now, Cramer believes that Immunogen is set to rebound behind the breast cancer drug T-DM1. T-DM1 is currently in Phase II of clinical trials and is set to replace the industry standard Herceptin. The results of the clinical trials will be released on Dec. 12.
The next company on Cramer’s list is Dendreon (NASDAQ: DNDN) which is an acquisition target for Bristol Myer Squibb or Merck. The interest on this company is fueled by the drug Provenge, which is in the late stages of development and estimated to be released to the commercial market by the middle of 2010. Sales for Provenge is expected to reach $730 million by 2011 and $4 billion by 2020. Shares for Dendreon were up 2.45% to $29.31.
On his final play, Cramer picked Exelixis (NASDAQ EXEL) because of their drug XL184, a drug designed to stop tumor growth. Exelixis is currently working with large partners in the development of XL184 and these companies include Bristol Myers Squibb, Roche (NASDAQ: RHHBY), and Sanofi Aventis (NYSE: SNY). Cramer picks EXEL as a highly speculative stock and its success is dependent on the success of XL184 and its potential in the Merger and Acquisition market as larger companies tend to buy out their smaller partners.
For the complete list of Cramer’s Picks for Cancer Cures you can go to this link:
http://www.cnbc.com/id/33728388/?slide=1
[ 本帖最后由 m.i.k.e 于 10-11-2009 03:07 PM 编辑 ] |
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2000 
84
